Drug Profile
Research programme: antibody-drug conjugates - Daiichi Sankyo/Seagen
Latest Information Update: 18 Dec 2023
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Inc; Seattle Genetics
- Developer Daiichi Sankyo Inc; Seagen
- Class Antibodies; Drug conjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours